Dupilumab use is associated with protection from COVID-19 mortality: A retrospective analysis.
Alexandra N DonlanIndika MallawaarachiJennifer M SassonRobert PreissnerJohanna J LoombaWilliam A PetriPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)
We previously found that type 2 immunity promotes COVID-19 pathogenesis in a mouse model. To test relevance to human disease we used electronic health record databases and determined that patients on dupilumab (anti-IL-4R monoclonal antibody that blocks IL-13 and IL-4 signaling) at the time of COVID-19 infection had lower mortality.
Keyphrases
- electronic health record
- monoclonal antibody
- coronavirus disease
- sars cov
- mouse model
- end stage renal disease
- atopic dermatitis
- cardiovascular events
- chronic kidney disease
- endothelial cells
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- risk factors
- clinical decision support
- prognostic factors
- cardiovascular disease
- respiratory syndrome coronavirus
- coronary artery disease
- patient reported outcomes
- induced pluripotent stem cells
- artificial intelligence
- pluripotent stem cells